TNF and Crohn disease: The 2024 ECCO Guidelines on Therapeutics in Crohn’s Disease: Surgical Management, as mentioned previously, “recommend against cessation of biologics prior to surgery as the current evidence suggests that preoperative treatment with anti-TNF therapy, vedolizumab and ustekinumab does not increase the risk of postoperative complications in CD patients undergoing abdominal surgery” [14].